Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABAT | P80404 | 3/20 | 1.00 |
| ▸ | OAT | P04181 | 1/20 | 0.66 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cpp-115 Free Base SCHEMBL2407298 | 1.00 | ABAT (1.00) | ABATOATGABRR1PLGPLAT | |
| Cpp-115 Free Base SCHEMBL21404893 | 1.00 | ABAT (1.00) | ABATOATGABRR1PLGPLAT | |
| Cpp-115 Free Base SCHEMBL12258069 | 1.00 | ABAT (1.00) | ABATOATGABRR1PLGPLAT | |
| Cpp-115 Free Base SCHEMBL2408171 | 1.00 | ABAT (1.00) | ABATOATGABRR1PLGPLAT | |
| Cpp-115 Free Base SCHEMBL15142226 | 0.98 | ABAT (0.96) | ABATOATGABRR1PLGPLAT | |
| Cpp-115 Free Base SCHEMBL14687433 | 0.98 | ABAT (0.96) | ABATOATGABRR1PLGPLAT | |
| SCHEMBL17742869 | 0.82 | ABAT (0.69) | ABATOATGABRR1SLC6A12SLC6A11 | |
| SCHEMBL29317652 | 0.81 | ABAT (0.68) | ABATOATGABRR1PLGPLAT | |
| SCHEMBL29276849 | 0.81 | ABAT (0.68) | ABATOATGABRR1PLGPLAT | |
| SCHEMBL29318645 | 0.81 | ABAT (0.68) | ABATOATGABRR1PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660277-B2 | Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders | OVID THERAPEUTICS INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210100763-A1 | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS, (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND VIGABATRIN IN THE TREATMENT OF DEVELOPMENTAL DISORDERS | OVID THERAPEUTICS INC. | 2021-04-08 | — | — | US | disclosed |
| US-9603820-B2 | Ornithine aminotransferase inhibition with GABA analogues for treatment of hepatocellular carcinoma | NORTHWESTERN UNIVERSITY (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2542234-A2 | METHODS OF USING (1S, 3S) -3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANOIC ACID | North Western University (US) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011106692-A2 | METHODS OF USING (1S, 3S) -3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANOIC ACID | NORTHWESTERN UNIVERSITY (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660277-B2 | Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders | GABRD, GABBR1, GABRA1 | ABAT 107/4885OAT 2530/4885GABRR1 31/4885 |
| US-20210100763-A1 | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS, (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND VIGABATRIN IN THE TREATMENT OF DEVELOPMENTAL DISORDERS | GABRD, GABBR1, GABRA1 | ABAT 107/4885OAT 2530/4885GABRR1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.